U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
CAMBRIDGE, Mass., Oct. 27, 2016 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call and audio webcast on Thursday, November 3, 2016, at 8:30 a.m. Eastern Time to report recent company highlights and third quarter 2016 financial results.
To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 96812020. The webcast can be accessed under "Events and Presentations" in the Investor Center section of the company's website at www.epizyme.com.
About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients. For more information, visit www.epizyme.com.
Contacts: Media: Julie DiCarlo, Epizyme, Inc. (617) 306-5823 [email protected] Investors: Monique Allaire, THRUST IR 617-895-9511 [email protected]
